Clinical Trials on Recurrent Skin Squamous Cell Carcinoma in South Africa

Total 1691 results

National Cancer Institute (NCI)

Recruiting

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage... and other conditions

Canada, United States
Novartis Pharmaceuticals

Terminated

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

France, Taiwan, United States, Australia, Canada, Hong Kong, Singapore, Korea, Republic of, Netherlands
PDS Biotechnology Corp.
Merck Sharp & Dohme LLC

Active, not recruiting

Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC (VERSATILE002)

HPV Positive Oropharyngeal Squamous Cell Carcinoma | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Neoplasms, Head and Neck

United States, Puerto Rico, Ireland, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Recurrent Esophageal Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Esophageal Cancer AJCC v7 | Metastatic Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Recurrent Esophageal Adenocarcinoma and other conditions

United States
University of Arizona
National Cancer Institute (NCI)

Completed

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

Head and Neck Cancer | Recurrent Head and Neck Squamous Cell Carcinoma | Oropharyngeal Cancer | HNSCC | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma | Stage IVA Nasal Cavity and... and other conditions

United States
National Cancer Institute (NCI)

Completed

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma

United States
Sung Hyun Pyun

Unknown

Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope

Skin Cancer

Australia
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

Skin Cancer | Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Locally Advanced Skin Squamous Cell Carcinoma | Locally Advanced Cutaneous Squamous Cell Carcinoma | Locally Advanced Squamous Cell Carcinoma | Locally Advanced Squamous Cell Carcinoma of the Skin

United States
International Atomic Energy Agency
Tata Memorial Centre; University of Maryland, College Park; Centro de Lucha contra... and other collaborators

Unknown

Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial (HYPNO)

Squamous Cell Carcinoma of the Head and Neck

India, Argentina, Cuba, Indonesia, Pakistan, Philippines, South Africa, Thailand, Uruguay
Sanofi

Completed

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Neoplasms | Neoplasm Metastasis | Neoplasm Recurrence, Local

Russian Federation, United States, Canada, Germany, Hungary, Italy, South Africa, Argentina, Uruguay, Austria, Switzerland, Israel, Belgium, France, Australia, Brazil, Greece, Guadeloupe, Réunion, Spain
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Oropharyngeal Squamous... and other conditions

United States, Puerto Rico, South Africa
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Nasopharyngeal Carcinoma | Current Smoker | Head and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Hypopharyngeal Squamous Cell Carcinoma | Laryngeal Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma

United States
Amgen

Completed

PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck

United States, Belgium, Czechia, Spain, Austria, France, Lithuania, Puerto Rico, Slovakia
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC; University of Stellenbosch

Withdrawn

Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

HIV Infection | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | FIGO Stage IIB Cervix Carcinoma | FIGO Stage III Cervix Carcinoma | FIGO Stage IVA Cervix Carcinoma

South Africa, Zimbabwe
Replimune Inc.
Regeneron Pharmaceuticals

Active, not recruiting

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS)

Cutaneous Squamous Cell Carcinoma | Advanced Cutaneous Squamous Cell Carcinoma | Metastatic Cutaneous Squamous Cell Carcinoma

Spain, United States, France, Australia, Germany, Canada, Greece, Bulgaria, Italy, Poland
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Terminated

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Metastatic Nasopharyngeal Nonkeratinizing Carcinoma | Metastatic Nasopharyngeal Undifferentiated Carcinoma | Nasopharyngeal... and other conditions

United States, Canada, China, Singapore
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Small Cell Squamous Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Recurrent Lung Adenocarcinoma | Loss of Heterozygosity | Recurrent... and other conditions

United States
Melanoma and Skin Cancer Trials Limited
Monash University; The University of Queensland

Not yet recruiting

Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin) (SiroSkin)

Skin Cancer | Solid Organ Transplant Recipients

Australia
Royal North Shore Hospital

Not yet recruiting

De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE) (DE-RADIATE)

HPV Positive Oropharyngeal Squamous Cell Carcinoma

Australia
National Cancer Institute (NCI)
NRG Oncology

Completed

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IVB Cervical Cancer AJCC v6 and v7

United States
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma

United States, Germany, Australia
University of Florida
Naveris, Inc.

Recruiting

Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma

Oropharyngeal Squamous Cell Carcinoma

United States
Antiva Biosciences

Completed

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.

Cervical Cancer | Human Papilloma Virus | HSIL, High Grade Squamous Intraepithelial Lesions | Cervical Dysplasia | HSIL of Cervix | High-Grade Cervical Intraepithelial Neoplasia | HIV Negative | CIN - Cervical Intraepithelial Neoplasia | Cervical Neoplasm

South Africa
AstraZeneca
PRA Health Sciences

Completed

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck

United States, Canada, France, Spain, Belgium, Czechia, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Australia, Germany, Georgia, Israel
Benitec BioPharma Ltd

Completed

A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

Australia, Russian Federation
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Skin Squamous Cell Carcinoma | Metastatic Skin Cancer

United States
Sanford Health

Completed

Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma

Squamous Cell Carcinoma of the Head and Neck

United States
Medical University of South Carolina

Recruiting

Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Terminated

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Recurrent Lung Adenocarcinoma | Stage IV Lung Adenocarcinoma | Recurrent Large Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma | Stage IV Large Cell Lung Carcinoma

United States, Mexico
Queensland Health
Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma (DESQUAMATE)

Head and Neck Cancer | Cutaneous Squamous Cell Carcinoma of the Head and Neck

Australia
Trans Tasman Radiation Oncology Group

Active, not recruiting

Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPVOropharynx)

HPV Positive Oropharyngeal Squamous Cell Carcinoma

Australia, New Zealand
National Cancer Centre, Singapore
National Medical Research Council (NMRC), Singapore; Innogene Kalbiotech Pte...

Active, not recruiting

Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer

Carcinoma, Squamous Cell of Head and Neck

Philippines, Thailand, Korea, Republic of, Australia, Taiwan, India, Saudi Arabia, Singapore, South Africa, Egypt, Cuba, Indonesia, Malaysia
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Olaparib in LA-HNSCC

Squamous Cell Carcinoma of Head and Neck

United States
Sanofi
Groupe Oncologie Radiotherapie Tete et Cou

Completed

TRACE: Tirapazamine-Radiation And Cisplatin Evaluation (TRACE)

Head and Neck Squamous Cell Carcinoma

United States, France, Canada, Poland, Germany, Spain, Switzerland, Singapore, Taiwan, Argentina, Hungary, Italy, Chile, Hong Kong, South Africa, Australia, New Zealand
Trisha Wise-Draper
Merck Sharp & Dohme LLC

Active, not recruiting

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

United States
Presage Biosciences
AstraZeneca

Recruiting

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC

Head and Neck Squamous Cell Carcinoma

United States
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)

Belgium, Australia, United States
Incyte Corporation

Recruiting

A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma

United States, Korea, Republic of, Spain, Brazil, France, Turkey, Canada, Mexico, Chile, Australia, Romania, South Africa, Colombia, Finland, Hungary, Montenegro, New Zealand, Croatia, Netherlands, North Macedonia
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Terminated

Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence

Head and Neck Squamous Cell Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Advanced Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of Unknown Primary | Advanced Hypopharyngeal Squamous Cell Carcinoma | Advanced Laryngeal Squamous Cell Carcinoma | Advanced Oropharyngeal Squamous Cell Carcinoma

United States, Canada
Washington University School of Medicine
Celgene Corporation

Active, not recruiting

Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) (APA)

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and Neck | Carcinoma, Squamous Cell of the Head and Neck

United States
Merck Sharp & Dohme LLC

Completed

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States, Australia, Austria, Brazil, France, Israel, Korea, Republic of, Norway, Spain, United Kingdom
Celldex Therapeutics

Terminated

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Advanced Head and Neck Squamous Cell Carcinoma

United States
Cascadian Therapeutics Inc.

Completed

Phase 1 and 2 Study of PX-866 and Cetuximab

Incurable Metastatic Colorectal Carcinoma | Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

United States, Canada
Medical University of South Carolina

Completed

Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT)

Head and Neck Squamous Cell Carcinoma | Body Image Disturbance

United States
ALX Oncology Inc.
Merck Sharp & Dohme LLC

Recruiting

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States, Belgium, Spain, Australia
Washington University School of Medicine
Celgene Corporation

Active, not recruiting

Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (CACTUX)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Cancer of the Head and Neck

United States

Clinical Trials on Recurrent Skin Squamous Cell Carcinoma in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations